# Alza Corporation, DE, USA clinical trials: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Alza Corporation, DE, USA as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alza Corporation, DE, USA: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/alza-corporation-de-usa

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2010 | NCT01230762 | An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation | Alza Corporation, DE, USA | Phase 3 | Completed | Ejaculation, Erectile Dysfunction, Sexual Dysfunction | 1,774 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01230762) |
| October 6, 2009 | NCT00990418 | Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System | Alza Corporation, DE, USA | Phase 1 | Completed | Pain, Postoperative | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00990418) |
| July 14, 2008 | NCT00714584 | Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers | Alza Corporation, DE, USA | Phase 1 | Completed | Biological Availability | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00714584) |
| July 14, 2008 | NCT00714558 | Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers | Alza Corporation, DE, USA | Phase 1 | Completed | Biological Availability | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00714558) |
| April 24, 2008 | NCT00666393 | An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients | Alza Corporation, DE, USA | Phase 3 | Withdrawn | Pain, Postoperative, Pediatrics | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00666393) |
| April 24, 2008 | NCT00665522 | A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg) | Alza Corporation, DE, USA | Observational | Terminated | Pain | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00665522) |
| April 1, 2008 | NCT00650182 | A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant | Alza Corporation, DE, USA | Phase 2 | Completed | Chronic Pain | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00650182) |
| January 22, 2007 | NCT00424931 | A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy | Alza Corporation, DE, USA | Phase 2 | Completed | Narcolepsy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00424931) |
| December 14, 2006 | NCT00411307 | A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term... | Alza Corporation, DE, USA | Phase 2 | Completed | Pain, Postoperative, Orthopedic Procedures, Analgesia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00411307) |
| December 13, 2006 | NCT00411268 | Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With... | Alza Corporation, DE, USA | Phase 3 | Completed | Low Back Pain | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00411268) |
| December 13, 2006 | NCT00411164 | A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis | Alza Corporation, DE, USA | Phase 3 | Completed | Osteoarthritis, Hip, Osteoarthritis, Knee | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00411164) |
| December 13, 2006 | NCT00411034 | A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain | Alza Corporation, DE, USA | Phase 3 | Completed | Analgesics, Opioid, Pain | 463 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00411034) |
| December 13, 2006 | NCT00410943 | Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets... | Alza Corporation, DE, USA | Phase 3 | Completed | Pain | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410943) |
| December 13, 2006 | NCT00410878 | A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain | Alza Corporation, DE, USA | Phase 1 | Completed | Pain, Analgesics, Opioid | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410878) |
| December 13, 2006 | NCT00410787 | Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain | Alza Corporation, DE, USA | Phase 3 | Completed | Analgesics, Opioid, Pain | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410787) |
| December 13, 2006 | NCT00410748 | Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release) | Alza Corporation, DE, USA | Phase 3 | Completed | Pain, Analgesics, Opioid | 388 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410748) |
| December 13, 2006 | NCT00410644 | A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain | Alza Corporation, DE, USA | Phase 3 | Completed | Pain, Analgesics, Opioid | 463 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410644) |
| December 13, 2006 | NCT00410540 | A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients. | Alza Corporation, DE, USA | Phase 3 | Completed | Pain, Analgesics, Opioid | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410540) |
| November 14, 2006 | NCT00399295 | An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic... | Alza Corporation, DE, USA | Phase 1 | Completed | Analgesia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00399295) |
| November 14, 2006 | NCT00399048 | An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release) | Alza Corporation, DE, USA | Phase 3 | Completed | Osteoarthritis, Knee, Osteoarthritis, Hip | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00399048) |
| November 14, 2006 | NCT00398957 | An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg | Alza Corporation, DE, USA | Phase 1 | Completed | Analgesia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00398957) |
| November 14, 2006 | NCT00398788 | A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl... | Alza Corporation, DE, USA | Phase 2 | Completed | Low Back Pain | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00398788) |
| November 7, 2006 | NCT00396422 | Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients... | Alza Corporation, DE, USA | Phase 2 | Completed | Chronic Small Plaque Psoriasis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00396422) |
| March 20, 2006 | NCT00304499 | Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence | Alza Corporation, DE, USA | Phase 3 | Completed | Urinary Incontinence | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00304499) |
| February 20, 2006 | NCT00293839 | Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder | Alza Corporation, DE, USA | Phase 3 | Completed | Urinary Incontinence | 790 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00293839) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 5 |
| Phase 3 | 25 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Terminated | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pain | 12 |
| Pain, Postoperative | 5 |
| Agnosia | 5 |
| Attention Deficit Disorder with Hyperactivity | 4 |
| Urinary Incontinence | 3 |
| Premature Ejaculation | 3 |
| Sexual Dysfunction, Physiological | 3 |
| Sexual Dysfunctions, Psychological | 3 |
| Coitus | 3 |
| Low Back Pain | 2 |
| Cancer Pain | 2 |
| Osteoarthritis, Hip | 2 |
| Osteoarthritis, Knee | 2 |
| Chronic Pain | 2 |
| Neoplasms | 2 |
| Urinary Incontinence, Urge | 1 |
| Osteoarthritis | 1 |
| Erectile Dysfunction | 1 |
| Psoriasis | 1 |
| Narcolepsy | 1 |
| Sleepiness | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B secretarial companies in the United States](https://specstream.ai/data/businesses/b2b-secretarial-companies/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [Industrial cleaning companies in the United States](https://specstream.ai/data/businesses/industrial-cleaning-companies/united-states)
- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [B2B scientific equipment companies in the United States](https://specstream.ai/data/businesses/b2b-scientific-equipment-companies/united-states)
